Literature DB >> 9616767

Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis.

D A Hafler1, S C Kent, M J Pietrusewicz, S J Khoury, H L Weiner, H Fukaura.   

Abstract

Oral administration of antigen is a long-recognized method of inducing systemic immune tolerance. In animals with experimental autoimmune disease, a major mechanism of oral tolerance involves the induction of regulatory T cells that mediate active suppression by secreting the cytokine TGF-beta 1. Multiple sclerosis (MS) is a presumed T cell-mediated Th1 type autoimmune disease. In this paper we investigated, in patients with MS, whether oral myelin treatment (myelin containing both MBP and PLP) induced antigen-specific MBP- or PLP-reactive T cells that were either Th2-like (secreted IL-4 or TGF-beta 1), or alternatively whether Th1 type sensitization occurred as measured by IFN-gamma secretion. Specifically, 4,860 short-term T cell lines were generated to either MBP, PLP or TT from 34 relapsing-remitting patients with MS; 17 were orally treated with bovine myelin daily for a minimum of two years as compared to 17 non-treated patients. We found a marked increase in the relative frequencies of both MBP- and PLP-specific TGF-beta 1 secreting T cell lines in the myelin-treated MS patients as compared to non-treated MS patients (MBP, p < 0.001; PLP, p < 0.003). In contrast, no changes in the frequency of MBP- or PLP-specific IFN-gamma or TT-specific TGF-beta 1 secreting T cells were observed. These results suggest that the oral administration of antigens generates antigen-specific TGF-beta 1 secreting T cells of presumed mucosal origin that may represent a distinct cytokine-secreting lineage of T cells (Th3). Since, in animal models, antigen-specific TGF-beta 1 secreting cells localize to the target organ and then suppress inflammation in the local microenvironment, oral tolerization with self-antigens may provide a therapeutic approach for the treatment of cell-mediated autoimmune disease which does not depend upon knowledge of the antigen specificity of the original T cell clone triggering the autoimmune cascade.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9616767     DOI: 10.1111/j.1749-6632.1997.tb48623.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

Review 1.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Authors:  Nitin J Karandikar; Michael P Crawford; Xiao Yan; Robert B Ratts; Jason M Brenchley; David R Ambrozak; Amy E Lovett-Racke; Elliot M Frohman; Peter Stastny; Daniel C Douek; Richard A Koup; Michael K Racke
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 3.  Biologia Futura: Emerging antigen-specific therapies for autoimmune diseases.

Authors:  Gabriella Sármay
Journal:  Biol Futur       Date:  2021-02-04

4.  The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy.

Authors:  David Thomas; Paola Zaccone; Anne Cooke
Journal:  Rev Diabet Stud       Date:  2005-05-10

5.  Association of Expanded Disability Status Scale and Cytokines after Intervention with Co-supplemented Hemp Seed, Evening Primrose Oils and Hot-natured Diet in Multiple Sclerosis Patients(♦).

Authors:  Soheila Rezapour-Firouzi; Seyed Rafie Arefhosseini; Mehdi Farhoudi; Mehrangiz Ebrahimi-Mamaghani; Mohammad-Reza Rashidi; Mohammad-Ali Torbati; Behzad Baradaran
Journal:  Bioimpacts       Date:  2012-10-28

Review 6.  Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.

Authors:  Tanuja Chitnis; Samia J Khoury
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  Exosome removal as a therapeutic adjuvant in cancer.

Authors:  Annette M Marleau; Chien-Shing Chen; James A Joyce; Richard H Tullis
Journal:  J Transl Med       Date:  2012-06-27       Impact factor: 5.531

Review 8.  Induction of Antigen-Specific Tolerance in T Cell Mediated Diseases.

Authors:  Laura Passerini; Silvia Gregori
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

9.  Suppressor T cells in human diseases.

Authors:  Clare Baecher-Allan; David A Hafler
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

Review 10.  The role of CD4 T cells in the pathogenesis of multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.